Adverse Drug Reactions and American College of Rheumatology

Selected news for the healthcare topic - Adverse Drug Reactions, and the healthcare topic - American College of Rheumatology. We have 9 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/19/2021 American College of Rheumatology Releases Position Statement on Patient Safety and Site of Service for Biologics The American College of Rheumatology (ACR)‚Aos Committee on Rheumatologic Care released an updated position statement regarding patient safety and the site of service for biologics for patients with rheumatic diseases. The full report is ... vs SC administration has been found to have more severe adverse drug reactions. Continue Reading Known adverse effects include injection site reactions; infusion reactions; infections including tuberculosis; cytopenia; increased risk for skin cancer; demyelinating diseases ...
9/29/2020 U.S. FDA Approves Pfizers XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Financial Buzz ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7 In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below. “Many ...
9/29/2020 U.S. FDA Approves Pfizer’s XELJANZ (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients.Please see important safety information below."Many children ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Pfizer ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7 In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below. “Many ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis BioSpace ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7 In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below. “Many ...
9/28/2020 U.S. FDA Approves Pfizer's XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis - GuruFocus.com ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7 In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients.Please see important safety information below. “Many children ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis | Business Wire Business Wire ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many ...
9/28/2020 ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many ...
9/28/2020 U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis Business Wire ... 6b The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase ... trials) after randomization , 6e,7In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.“Many ...